Alcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Pancreatitis Patients at Massachusetts General Hospital
WALTHAM, Mass., April 29, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that Massachusetts General Hospital (MGH) has enrolled the first patient in an investigator-initiated trial evaluating the efficacy of RELiZORB in managing exocrine pancreatic insufficiency (EPI) in tube-fed pancreatitis patients.
'We are excited about the enrollment of the first patient in this study to evaluate the potential benefits of RELiZORB use in tube-fed pancreatitis patients. Acute pancreatitis is one of the leading gastrointestinal causes of hospital admissions, and there is a growing focus on managing long-term complications of pancreatitis, which includes EPI,' said Casey Luckhurst, MD, Pancreatic and General Surgeon and Inpatient Director of Massachusetts General Hospital's Pancreatitis Treatment Center.
Fat malabsorption is often associated with EPI conditions including pancreatitis, cystic fibrosis, and gastrointestinal cancers and can result in weight loss and serious gastrointestinal symptoms. For patients with fat malabsorption who require tube feeding, RELiZORB is the only FDA-cleared enzyme device designed to mimic the function of pancreatic lipase to improve absorption of fats for tube-fed patients. Studies have demonstrated that RELiZORB is safe, well-tolerated, and effective in improving fat absorption for patients with cystic fibrosis.
'The initiation of study recruitment marks an important step toward expanding the body of clinical evidence that supports RELiZORB use in Alcresta's target therapeutic areas,' said Michael Yeh, MD, Senior Vice President of Medical Affairs at Alcresta Therapeutics. 'This is one of four clinical trials evaluating the safety and efficacy of RELiZORB in malabsorptive conditions supporting our mission to improve nutritional care and outcomes for tube-fed patients living with rare diseases.'
For more information about RELiZORB clinical trials, visit ClinicalTrials.gov:
About RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE
RELiZORB is a first-of-its-kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase and is indicated for use in pediatric patients (ages 1 year and above) and adult patients to hydrolyze fats in enteral formula. RELiZORB was developed using Alcresta's proprietary enzyme immobilization technology, iLipase®, which is the digestive enzyme lipase bound to small polymeric bead carriers. RELiZORB connects in-line to enteral feeding systems. As enteral formula passes through RELiZORB, the bound lipase breaks down formula fats into an absorbable form prior to ingestion. RELiZORB was FDA-cleared in 2015 for use in adult patients and was cleared in 2017 for use in children as young as five years old. Use was expanded to pediatric patients as young as two years old in August 2023 and expanded again for patients as young as one year old in January 2025. The next-generation RELiZORB device was introduced to market in May 2024 with broader formula compatibility, an increase in the number of devices used per day and use in both continuous and bolus-feeding set ups.
About Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Alcresta currently markets RELiZORB for enterally-fed patients with pancreatic insufficiency, which occurs in cystic fibrosis, pancreatic cancer, and pancreatitis, and short bowel syndrome, which is marked by significant malabsorption due to limited absorptive area as a result of resection. Alcresta is currently developing a platform application for prematurely born infants treated in the NICU. Alcresta Therapeutics, Inc. is backed by Linden Capital Partners and HealthQuest Capital. More information can be found at www.alcresta.com.
Internal Media Contact:
Natalie Bronfin
Alcresta Therapeutics, Inc.
[email protected]
617-431-3600
View original content: https://www.prnewswire.com/news-releases/alcresta-therapeutics-announces-enrollment-of-first-patient-in-clinical-trial-evaluating-use-of-relizorb-in-pancreatitis-patients-at-massachusetts-general-hospital-302440918.html
SOURCE Alcresta Therapeutics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
Yahoo
5 hours ago
- Yahoo
How Is Hologic's Stock Performance Compared to Other Health Care Equipment Stocks?
With a market cap of $14.3 billion, Hologic, Inc. (HOLX) is a Massachusetts-based medical technology firm, primarily focused on women's health. The company develops, manufactures, and sells a comprehensive suite of solutions, including molecular diagnostics, medical imaging systems, and surgical devices Companies worth $10 billion or more are generally described as 'large-cap stocks,' and Hologic fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. The company benefits from robust innovation, supported by over 7,000 patents, which fuels its proprietary technologies and product differentiation. Its diagnostics segment, particularly in molecular testing, has shown strong growth, positioning Hologic well in the expanding global healthcare market. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, HOLX shares have retreated 24.5% from their 52-week high of $84.67 touched on Aug. 9, 2024. Meanwhile, HOLX stock has surged 3.2% over the past three months, surpassing the SPDR S&P Health Care Equipment ETF's (XHE) 4.8% plunge over the same time frame. HOLX stock has plummeted 11.3% on a YTD basis and 10.5% over the past 52 weeks, compared to XHE's 10.6% dip in 2025 and a 6.3% fall over the past year. The stock has remained consistently below its 200-day moving average since early December last year, but has climbed above its 50-day moving average since late May. On May 27, HOLX shares surged more than 14%, leading S&P 500 gainers, after reports emerged that TPG Inc. (TPG) and Blackstone Inc. (BX) made (and were turned down on) a non-binding ~$16 billion takeover bid, valuing the company at $70–$72 per share. The stock's rally reflected investor optimism and underscored the premium valuation placed on its leadership in women's health and diagnostic capabilities. In the competitive healthcare equipment industry, top rival, Align Technology, Inc.'s (ALGN) 13.7% drop on a YTD basis and 25.7% decline over the past year trails HOLX's losses in the same time frames. Among the 19 analysts covering the HOLX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $68.27 suggests a 6.7% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Business News
6 hours ago
- Time Business News
Prozenith Reviews 2025: The Pink Salt Trick That's Melting Fat Fast!
Official Website: Click Here What is ProZenith? ProZenith is a natural dietary supplement formulated to support effective weight management and overall well-being. It is designed for individuals seeking to enhance their metabolism, increase energy levels, and support fat burning without the use of harsh chemicals or stimulants. By promoting the body's natural ability to burn fat and boost energy, ProZenith helps users achieve and maintain a healthier lifestyle. The supplement is manufactured in FDA-registered and GMP-certified facilities, ensuring its quality and safety. It also supports better mental clarity, digestive health, and immune function. With consistent use and alongside a balanced diet and exercise, ProZenith becomes a reliable ally for anyone on a weight loss or wellness journey. Its plant-based formula makes it a suitable option for those who prefer natural health solutions. Users often report improvements not only in physical performance but also in mood, focus, and daily motivation. The Science Behind ProZenith ProZenith operates on the scientific principle of metabolic enhancement. It helps the body enter a state where fat is used as the primary source of fuel rather than carbohydrates, a process similar to ketosis. This metabolic shift increases energy efficiency and encourages fat loss. Additionally, it supports hormonal balance and appetite regulation, helping reduce unnecessary cravings. This supplement promotes better nutrient absorption and reduces bloating, which further supports the weight loss process. By combining natural compounds known for their holistic benefits, ProZenith addresses various aspects of health to provide a science-backed, safe path to sustainable weight management. Ingredients of ProZenith The ingredients in ProZenith are carefully selected natural compounds known for supporting weight management, energy production, and overall wellness. Each component plays a unique role in promoting metabolism, enhancing fat burning, reducing inflammation, and supporting hormonal balance. Pumpkin Seed Pumpkin seed is renowned for its high antioxidant content and essential fatty acids, which work synergistically to support prostate and urinary health. These nutrients help regulate hormonal balance, reduce inflammation, and protect against oxidative stress. Regular consumption can lead to improved bladder control and decreased discomfort, enhancing daily comfort and urinary function. Lycopene Lycopene is a potent antioxidant primarily found in tomatoes, celebrated for its ability to neutralize harmful free radicals and prevent cellular damage. This compound contributes significantly to immune system support and reduces inflammation throughout the body. Its protective effects extend to promoting heart health and maintaining a healthy prostate, making it a vital nutrient for overall wellness. Broccoli Broccoli is a nutrient-dense vegetable rich in sulforaphane, a natural compound with powerful detoxifying and anti-inflammatory properties. Sulforaphane helps protect cells from damage, supports the body's detoxification pathways, and enhances immune defenses. Additionally, broccoli supports digestive health by improving gut function and reducing inflammation in the digestive tract. Beta Sitosterol Beta Sitosterol is a plant-derived sterol known for its ability to improve urinary flow and support prostate health. It helps maintain balanced cholesterol levels and promotes hormonal equilibrium, which is essential for men experiencing symptoms of an enlarged prostate. Beyond urinary benefits, Beta Sitosterol also supports cardiovascular health and overall well-being. Pygeum Africanum Bark Extracted from the African cherry tree, Pygeum Africanum Bark has a long history in traditional medicine for supporting urinary tract and prostate health. It helps reduce inflammation, ease discomfort during urination, and lessen the frequency of nighttime bathroom visits. Its anti-inflammatory and soothing properties contribute to improved urinary flow and enhanced quality of life. Benefits Accelerated Fat Burning: Helps your body shift into a fat-burning mode by enhancing metabolism, promoting sustainable weight loss. Helps your body shift into a fat-burning mode by enhancing metabolism, promoting sustainable weight loss. Appetite Control: Naturally reduces cravings and supports better portion control to help avoid overeating. Naturally reduces cravings and supports better portion control to help avoid overeating. Increased Energy Levels: Boosts energy without relying on stimulants, helping you stay active and alert throughout the day. Boosts energy without relying on stimulants, helping you stay active and alert throughout the day. Enhanced Mental Clarity: Supports cognitive functions like focus, memory, and motivation—key for staying consistent with health goals. Supports cognitive functions like focus, memory, and motivation—key for staying consistent with health goals. Improved Digestive Health: Aids gut function by reducing bloating and enhancing nutrient absorption for better overall health. Aids gut function by reducing bloating and enhancing nutrient absorption for better overall health. Immune System Support: Strengthens your body's natural defenses to keep you healthier while managing weight. Pros Natural formula Supports weight loss Boosts energy Enhances focus Improves mood Reduces cravings Promotes fat burning Aids digestion Non-GMO and stimulant-free Backed by a money-back guarantee Cons Only available online Not suitable for children Results may vary Requires consistent use How To Use? Take two ProZenith capsules daily with a glass of water, preferably before meals. For best results, follow a consistent routine and support it with a healthy diet and regular physical activity. This helps maximize the supplement's benefits and promotes long-term well-being. Any Side Effects? ProZenith has no side effects when taken as directed, thanks to its natural, non-GMO, plant-based ingredients. Users commonly report increased energy levels and enhanced metabolism without any discomfort or adverse reactions. Its gentle and carefully crafted formula is designed for daily use and is well-tolerated by most individuals. This makes ProZenith a safe and reliable option for those looking to support their health and weight management naturally, without the worry of unwanted side effects or harsh stimulants. Money Back Guarantee ProZenith comes with a 60-day money-back guarantee, giving you the confidence to try it risk-free. If within 60 days you feel the supplement doesn't meet your expectations or you're not satisfied with the results, you can easily request a full refund by contacting customer support. This generous refund policy ensures you have ample time to evaluate the product's effectiveness without any financial worry. With this guarantee, ProZenith offers a worry-free opportunity to invest in your health and well-being, making it a trustworthy choice for those seeking natural support. Pricing & Availability Basic Pack (2 Bottles): $158 + $9.99 Shipping Most Popular (3 Bottles): $207 with Free Shipping Best Value (6 Bottles): $294 with Free Shipping and the biggest savings Where to Buy? ProZenith can be purchased exclusively through its official website. This ensures you're getting the authentic product, complete with quality assurance, secure checkout, and eligibility for bonuses and money-back guarantees. Avoid third-party platforms that may sell counterfeit versions. Buying directly also gives you access to customer support and the latest promotional offers. For your safety and best experience, always purchase from the verified source. Conclusion As an expert, I strongly recommend ProZenith for anyone seeking a natural and effective solution to support weight management and overall wellness. This supplement uses powerful plant-based ingredients that work together to boost metabolism, increase energy, and promote fat burning without harsh chemicals or stimulants. It also enhances mental clarity and supports digestive health, making it ideal for daily use. With regular use, ProZenith helps achieve sustainable results while strengthening the immune system. Supported by positive customer reviews and a 60-day money-back guarantee, it offers a risk-free way to improve your health. If you want a reliable, natural boost to your wellness journey, ProZenith is definitely worth trying. >> (LIMITED SUPPLIES) Click Here to Buy ProstaVive for The Lowest Price Online << TIME BUSINESS NEWS
